Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Open-label Trial Evaluating the Long-term Safety and Tolerability of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine

NCT03303105 is registered in ClinicalTrials.gov with Otsuka Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT03303105
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03303105 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Open-label Trial Evaluating the Long-term Safety and Tolerability of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine
Lead sponsor
Otsuka Pharmaceutical Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
December 7, 2017
Completion date
June 16, 2020
Enrollment
50 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

migraine